BP
TAK icon

Ballentine Partners’s Takeda Pharmaceutical TAK Stock Holding History

Ballentine Partners’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$482K Buy
30,095
+4,425
+17% +$73.2K 0.01% 580
2026
Q1 		$475K Buy
25,670
+2,177
+9% +$38.2K 0.01% 548
2025
Q4 		$366K Sell
23,493
-22,791
-49% -$326K 0.01% 628
2025
Q3 		$678K Sell
46,284
-1,750
-4% -$26K 0.01% 410
2025
Q2 		$743K Buy
48,034
+9,656
+25% +$143K 0.01% 377
2025
Q1 		$571K Sell
38,378
-284
-0.7% -$3.98K 0.01% 407
2024
Q4 		$512K Buy
38,662
+7,568
+24% +$104K 0.01% 418
2024
Q3 		$442K Buy
31,094
+10,205
+49% +$145K 0.01% 453
2024
Q2 		$270K Buy
20,889
+4,058
+24% +$53.7K 0.01% 597
2024
Q1 		$234K Sell
16,831
-1,497
-8% -$21.8K ﹤0.01% 624
2023
Q4 		$262K Sell
18,328
-1,640
-8% -$23.3K 0.01% 544
2023
Q3 		$309K Buy
19,968
+6,412
+47% +$99.3K 0.01% 438
2023
Q2 		$213K Buy
13,556
+2,816
+26% +$46.1K ﹤0.01% 540
2023
Q1 		$177K Buy
+10,740
New +$171K ﹤0.01% 531
2022
Q4 		– Sell
-21,416
Closed -$278K – 528
2022
Q3 		$278K Sell
21,416
-22
-0.1% -$306 0.01% 360
2022
Q2 		$301K Sell
21,438
-6,439
-23% -$91.9K 0.01% 325
2022
Q1 		$399K Buy
27,877
+9,548
+52% +$140K 0.01% 298
2021
Q4 		$249K Buy
+18,329
New +$257K 0.01% 398

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Ballentine Partners's TAK Position: Q2 2026 in Review

Ballentine Partners increased its Takeda Pharmaceutical (TAK) stake by 17% in Q2 2026, buying an estimated $73.2K and bringing the position to 30,095 shares worth $482K. The position accounts for 0.01% of the portfolio, ranked #580.

Ballentine Partners first reported a position in TAK in Q4 2021 and has held it in 18 quarters since. The position peaked at $743K in Q2 2025. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Ballentine Partners held 30,095 shares of Takeda Pharmaceutical worth $482K as of Q2 2026.
  • Ballentine Partners bought 4,425 Takeda Pharmaceutical shares in Q2 2026, an estimated $73.2K.
  • Takeda Pharmaceutical made up 0.01% of Ballentine Partners's portfolio in Q2 2026, its #580 holding.
  • Ballentine Partners first reported a position in Takeda Pharmaceutical in Q4 2021 and has held it in 18 quarters since.
  • Ballentine Partners's Takeda Pharmaceutical position peaked at $743K in Q2 2025.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.